Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users.
about
CCR5Delta32 mutation does not influence the susceptibility to HCV infection, severity of liver disease and response to therapy in patients with chronic hepatitis C.25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settingsAssociation of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection.Antimicrobial implications of vitamin D.Influence of host genetic variation on susceptibility to HIV type 1 infection.Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York.Vitamin D signaling, infectious diseases, and regulation of innate immunity.Prevalence of common vitamin D receptor gene polymorphisms in HIV-infected and uninfected South AfricansVitamin D-related host genetic variants alter HIV disease progression in childrenAdjudication of the alleged role of vitamin d in the antimicrobial pathway.Social and structural factors associated with HIV disease progression among illicit drug users: a systematic reviewRisk of HIV Infection and Lethality Are Decreased in CCR5del32 Heterozygotes: Focus Nosocomial Infection Study and Meta-analysis.Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.Association of vitamin D receptor genetic variants with susceptibility to asthma and atopy.Association of vitamin D receptor gene polymorphisms with childhood and adult asthma.Evaluation of 1,25-dihydroxyvitamin D3 Pathway in Patients with Chronic Urticaria.
P2860
Q33867870-DF271CC4-F62A-4033-A3F1-8A8D6379C440Q34076892-50ADAA27-01B3-4951-A975-2D9583C50DFBQ34311435-0B43E2F5-51E2-4E83-9FAA-B28622FC4516Q35667399-4A78F573-B2A1-4164-BAE8-7EA9321096BCQ35999000-F9AF5394-6B1D-4741-AA1F-E39D43D036D5Q36177899-F2110B30-837C-490D-9E07-35A6F6BFDA87Q36845164-2BC894EF-AB17-42C3-8F63-47956D239BF7Q36874968-77AFFFD4-31A5-4990-B654-2F63862C45EBQ37265049-C5C9BE16-13F6-41DD-A472-49A9BE6E7093Q37288171-25019020-9F05-4552-A332-FF519AEF961DQ37638817-C712542B-7DD2-4145-BA30-974AB528E0A9Q42003237-88AAAF58-4F14-4713-8A3E-D61B516B9845Q44394482-6131B712-88B9-4724-B370-024ACB9AF22DQ44999163-F6DBAD5F-9319-4F81-88B1-B0F8BF659DCAQ44999167-4AE5F1F9-6315-4D3D-9C6B-447C4F336446Q47374022-0D313AE1-1921-4C6F-8B52-D481FB9D6F39
P2860
Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Host genetic background at CCR ...... positive injection drug users.
@en
Host genetic background at CCR ...... d human immunodeficiency virus
@nl
type
label
Host genetic background at CCR ...... positive injection drug users.
@en
Host genetic background at CCR ...... d human immunodeficiency virus
@nl
prefLabel
Host genetic background at CCR ...... positive injection drug users.
@en
Host genetic background at CCR ...... d human immunodeficiency virus
@nl
P2093
P356
P1476
Host genetic background at CCR ...... opositive injection drug users
@en
P2093
P304
P356
10.1086/324000
P407
P50
P577
2001-10-15T00:00:00Z